Seems like Cowen’s HC and Biotech groups are killing it in deal flow. Anyone have any experience with them and have any thoughts on how they stack up against other groups in terms of deal flow/exit ops/culture?
| +305 | I Snuck Into UBS Office And Took A Shit On The Floor | 28 | 1d |
| +291 | TPH V.S. Mizuho [HOU] | 36 | 2d |
| +248 | Houston 2026 Oil & Gas Investment Banking Rankings | 61 | 2h |
| +244 | Why leave restructuring for M&A? | 30 | 1d |
| +232 | Best Power/Renewables/Energy Teams? | 39 | 7h |
| +193 | Predicted 1Q 2027 Story - UBS IB blames Outlook Outage for Down Quarter | 36 | 11h |
| +187 | Centerview HC group falling off? | 30 | 1d |
| +184 | Actual EB List | 27 | 1d |
| +180 | Incoming TPH Analysts Larping as PWP on LinkedIn | 26 | 4h |
| +21 | What’s the current state of IBD at BofA? | 26 | 14h |
Career Resources
Get instant access to lessons taught by experienced private equity pros and bulge bracket investment bankers including financial statement modeling, DCF, M&A, LBO, Comps and Excel Modeling.
Hi tgn005, check out these links:
I hope those threads give you a bit more insight.
bump. Any opinions would be helpful especially regarding exit ops.
Optio eos consequatur et ipsa excepturi aliquam. Expedita quisquam voluptatem sapiente ut explicabo id. Voluptatibus iure quod sit eaque cumque quae possimus velit. Repellendus veritatis tenetur vero eius et fugiat.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...